Galera Therapeutics (GRTX) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRTX shares.
View GRTX analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month target prices for Galera Therapeutics' stock. Their GRTX share price forecasts range from $6.00 to $12.00. On average, they expect the company's share price to reach $7.75 in the next year. This suggests a possible upside of 152.4% from the stock's current price.
View analysts price targets for GRTX or view top-rated stocks among Wall Street analysts.

Galera Therapeutics' stock was trading at $1.49 at the beginning of 2023. Since then, GRTX stock has increased by 106.0% and is now trading at $3.07.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our GRTX earnings forecast.

Galera Therapeutics, Inc. (NASDAQ:GRTX) released its quarterly earnings results on Wednesday, March, 8th. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.08.

Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), Ardelyx (ARDX), Chiasma (CHMA), Provention Bio (PRVB), Seelos Therapeutics (SEEL), Soligenix (SNGX), TG Therapeutics (TGTX) and VBI Vaccines (VBIV).

(GRTX) raised $75 million in an initial public offering on Thursday, November 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.

Galera Therapeutics trades on the NASDAQ under the ticker symbol "GRTX."

Galera Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sectoral Asset Management Inc. (4.89%), BlackRock Inc. (0.74%), Renaissance Technologies LLC (0.47%), Geode Capital Management LLC (0.46%), Schonfeld Strategic Advisors LLC (0.32%) and State Street Corp (0.19%). Insiders that own company stock include Bioventures Ltd Novartis, Chris Degnan, Holdings A/S Novo, Joel F Sussman, Jon T Holmlund, Linda West, Mark Bachleda and Mel Sorensen.
View institutional ownership trends.

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GRTX stock can currently be purchased for approximately $3.07.

Galera Therapeutics (NASDAQ:GRTX) has a market capitalization of $131.73 million. The company earns $-62,220,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis.

Galera Therapeutics' mailing address is 2 WEST LIBERTY BOULEVARD SUITE 100, MALVERN PA, 19355. The official website for the company is www.galeratx.com. The company can be reached via phone at 610-725-1500 or via email at cdegnan@galeratx.com.